Leveraging social media to increase lung cancer screening awareness, knowledge and uptake among high-risk populations (The INSPIRE-Lung Study): Study protocol of design and methods of a community-based randomized controlled trial

Author:

Carter-Bawa Lisa1,Banerjee Smita C2,Ostroff Jamie S2,Kale Minal S3,King Jennifer C4,Leopold Katherine T5,Monahan Patrick O6,Slaven James E6,Wiener Renda Soylemez7,Valenzona Francis1,Rawl Susan M8,Comer Robert Skipworth9

Affiliation:

1. Center for Discovery and Innovation at Hackensack Meridian Health

2. Memorial Sloan Kettering Cancer Center

3. Icahn School of Medicine at Mount Sinai

4. GO2 for Lung Cancer

5. Hackensack Meridian School of Medicine

6. Indiana University School of Medicine

7. VA Boston Healthcare System

8. Indiana University School of Nursing

9. Indiana University – Purdue University Indianapolis

Abstract

Abstract Background. Lung cancer is the leading cause of cancer death for both men and women in the United States. The National Lung Screening Trial (NLST) demonstrated that low-dose computed tomography (LDCT) screening can reduce lung cancer mortality among high-risk individuals, but uptake of lung screening remains low. Social media platforms have the potential to reach a large number of people, including those who are at high risk for lung cancer but who may not be aware of or have access to lung screening. Methods. This paper discusses the protocol for a randomized controlled trial (RCT) that leverages FBTA to reach screening-eligible individuals in the community at large and intervene with a public-facing, tailored health communication intervention (LungTalk) to increase awareness of, and knowledge about, lung screening. Discussion. This study will provide important information to inform the ability to refine implementation processes for national population efforts to scale a public-facing health communication focused intervention using social media to increase screening uptake of appropriate, high-risk individuals. Trial Registration: The trial is registered at clinicaltrials.gov (#NCT05824273).

Publisher

Research Square Platform LLC

Reference44 articles.

1. American Cancer Society. Cancer Facts & Figs. 2023. Atlanta, GA: American Cancer Society; 2023.

2. U.S. Preventive Services Task Force. Final recommendation statement: Lung cancer screening. 2020. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/lung-cancer-screening. Accessed April 19, 2023.

3. Reduced lung-cancer mortality with low-dose computed tomographic screening;Aberle DR;N Engl J Med,2011

4. ES 02.01 The Dutch-Belgian Lung Cancer Screening Trial (NELSON);Koning H;J Thorac Oncol,2017

5. Centers for Medicare & Medicaid Services. Decision memo for screening for lung cancer with low-dose computed tomography (LDCT) (CAG-00439N). https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274. Accessed March 21, 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3